Joel Isaacson & Co’s Evogene EVGN Stock Holding History

Joel Isaacson & Co’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,030	Closed	-$19.7K	–	376
2024 Q2	$19.7K	Hold	3,030	–	–	﹤0.01%	349
2024 Q1	$22.7K	Hold	3,030	–	–	﹤0.01%	334
2023 Q4	$25.5K	Hold	3,030	–	–	﹤0.01%	311
2023 Q3	$17.8K	Hold	3,030	–	–	﹤0.01%	306
2023 Q2	$32.4K	Buy	3,030 +30	+1%	+$203	﹤0.01%	319
2023 Q1	$18.9K	Hold	3,000	–	–	﹤0.01%	322
2022 Q4	$21K	Buy	+3,000	New	+$21.2K	﹤0.01%	319

Other funds holding EVGN

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

RIG

Renaissance Investment Group Lenox, Massachusetts $508M AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Joel Isaacson & Co's EVGN Position: Q3 2024 in Review

Joel Isaacson & Co sold out of Evogene (EVGN) in Q3 2024, closing a stake of 3,030 shares — an estimated $19.7K sold.

Joel Isaacson & Co first reported a position in EVGN in Q4 2022 and held it in 7 quarters. The position peaked at $32.4K in Q2 2023. 14 funds tracked by Wall St. Rank hold EVGN as of Q3 2024.

Joel Isaacson & Co reported no remaining Evogene position as of Q3 2024 after selling out during the quarter.
Joel Isaacson & Co sold 3,030 Evogene shares in Q3 2024, an estimated $19.7K.
Joel Isaacson & Co first reported a position in Evogene in Q4 2022 and held it in 7 quarters.
Joel Isaacson & Co's Evogene position peaked at $32.4K in Q2 2023.
14 funds tracked by Wall St. Rank held Evogene as of Q3 2024.

Based on Joel Isaacson & Co's 13F filing for Q3 2024, filed 23 Oct 2024.